Strategy

Amarna is focused on becoming a leader in developing viral vector technology that could revolutionize the treatment of a wide range of immunity-associated diseases. Its experienced management team has a clear strategy to realize the full commercial and clinical value of its SVac technology.

The key elements of this strategy are:
• Demonstration of clinical proof-of-concept covering safety and efficacy
• Demonstration of feasibility of a single administration
• Development of a focused pipeline of novel proprietary clinical candidates using its SVac platform
• Identification of key commercial and clinical partners to develop these proprietary therapeutics
• Generation of further value from SVac by out-licensing it to a range of partners
• Development of state-of-the-art production facilities for manufacturing SVac

In addition, Amarna plans to use an out-licensing approach to maximize the value it can generate from its PRP3 production platform. Potential licensees include companies interested in cost-effective and high-yielding therapeutic protein production technologies in mammalian cell systems.